Ladenburg Thalmann Upgrades Chelsea Therapeutics (CHTP) to Buy
More News related to CHTP
- Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 20th Annual International Symposium on the Autonomic Nervous System
- Unusual 11 Mid-Day Movers 11/03: LNY, BNI, DDRX, BDK Higher; CKEC, TPGI, CHTP, CMLS Lower
- Morning Movers 10/03: BNI, DDRX, BDK, AIMC, RTEC, MEDW Higher; CKEC, TPGI, IBCP, NSTC, CMLS, HEB Lower
- After-Hours Movers 11/02: BDK, DDRX, ATSI, HLF, HTCH, SNCR, CAR Higher; TNS, HIMX, SVR, TXRH Lower
- Chelsea Therapeutics (CHTP) Reports Better-Than-Expected Q3 Loss of $0.22
Ladenburg Thalmann upgrades Chelsea Therapeutics (Nasdaq: CHTP) to Buy, also setting a $5 price target.
The upgrade follows news earlier that additional analysis on Droxidopa confirmed a significant symptomatic benefit. Shares have rallied more than 24% today on the news.
To see all the analyst action on shares of Chelsea, visit our Analyst Ratings page.
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases.
Related Categories
UpgradesStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
